Ultrasound-Enhanced Cu Single-Atom SAzymes for Targeted Chemodynamic Therapy

Study Background and Research Question

Chemodynamic therapy (CDT) leverages endogenous hydrogen peroxide (H₂O₂) in the tumor microenvironment (TME) to generate cytotoxic reactive oxygen species (ROS), primarily hydroxyl radicals (•OH), to induce cancer cell death. However, CDT efficacy is often hampered by the low H₂O₂ content and high concentrations of reducing agents such as glutathione (GSH) within the TME. Traditional nanocatalysts—especially those based on metal clusters—face limitations including suboptimal metal atom utilization, uncontrolled catalytic sites, and potential toxicity. Single-atom nanoenzymes (SAzymes) offer a route to maximize catalytic efficiency and minimize adverse effects. The central research question addressed by the reference study concerns whether a copper single-atom-based metal-organic framework can be engineered to overcome these barriers, particularly through ultrasound (US) enhancement and precise in vivo imaging.

Key Innovation from the Reference Study

The reference paper reports the design and synthesis of FNUC, a copper single-atom nanoenzyme coordinated within a NH₂-UiO-66 metal-organic framework and modified with folic acid for tumor targeting. Uniquely, the system integrates three technological advances:

• Precise placement of Cu²⁺ single atoms, maximizing catalytic site utilization and minimizing systemic toxicity.
• Ultrasound-triggered enhancement of peroxidase-like activity, accelerating •OH production via the cavitation effect.
• In vivo tracking using NIR-II fluorescence imaging, achieved by conjugating the platform with the near infrared fluorescent dye IR-1061, enabling deep-tissue visualization of nanocatalyst distribution.

This multi-modal approach addresses both the biochemical and imaging challenges of CDT, pushing the field toward more effective and quantifiable nanocatalytic therapies.

Methods and Experimental Design Insights

The study employed a stepwise synthesis strategy:

• NH₂-UiO-66 frameworks were constructed and subsequently coordinated with single Cu²⁺ atoms, as confirmed by high-resolution transmission electron microscopy (HR-TEM), X-ray absorption spectroscopy (XAS), and extended X-ray absorption fine structure (EXAFS) analysis.
• Folic acid modification was performed to facilitate tumor targeting via folate receptor recognition.
• For in vivo tracking, the platform was labeled with IR-1061, a second-window near infrared fluorescent dye known for its deep tissue penetration and low background autofluorescence. The conjugation enabled real-time, non-invasive imaging during animal studies.

Key experiments included in vitro assessments of peroxidase-like and glutathione oxidase-like (GSHOx) activity, measurement of Michaelis constants, and ultrasound (US) irradiation to evaluate cavitation-enhanced ROS generation. In vivo efficacy and biodistribution were assessed in mouse tumor models, utilizing NIR-II fluorescence imaging for tracking.

Core Findings and Why They Matter

The FNUC SAzyme exhibited several notable properties:

• High Metal Atom Utilization: Single-atom dispersion of copper ensured nearly every atom contributed catalytically, enhancing efficiency and reducing potential for toxicity.
• Dual Enzymatic Function: FNUC operated both as a GSH-depleting agent and as a peroxidase mimic, enabling persistent ROS generation even in reductive TMEs.
• Ultrasound Enhancement: US irradiation significantly increased the •OH production rate, attributed to the cavitation effect, resulting in lower Michaelis constants and higher ROS concentrations than non-irradiated controls (reference study).
• Precise Tumor Targeting and Imaging: NIR-II fluorescence imaging (enabled by IR-1061 labeling) confirmed FNUC accumulation at tumor sites, facilitating non-invasive monitoring of therapeutic distribution and kinetics.
• In Vivo Efficacy: Animal studies demonstrated potent tumor suppression with minimal systemic toxicity, underscoring the translational potential of this approach.

Collectively, these findings illustrate that combining single-atom catalysis, ultrasound activation, and advanced optical imaging can overcome classic CDT bottlenecks, offering a robust framework for future nanoenzyme development.

Comparison with Existing Internal Articles

Several recent reviews and technical guides have addressed the integration of NIR-II dyes in nanocatalytic therapy platforms. For example, the internal article "IR-1061: Enabling Precision NIR-II Imaging in Nanocatalytic Therapy" provides a mechanistic overview of how IR-1061-based labeling supports real-time optical tracking of single-atom nanoenzyme biodistribution, resonating with the imaging strategy used in the reference study. Similarly, "IR-1061 Near Infrared Fluorescent Dye: Protocols & Deep Imaging" offers protocol-level recommendations for dye encapsulation and troubleshooting, which are directly relevant for researchers seeking to adapt the FNUC workflow for other molecular imaging probes or alternative dye systems. These resources collectively reinforce the importance of optimized NIR-II fluorescent dye integration for maximizing the translational value of nanocatalytic cancer therapies.

Limitations and Transferability

While the FNUC platform demonstrates significant advancements, several limitations should be considered:

• Stability and Scalability: The synthesis of single-atom SAzymes requires stringent conditions and may present scalability challenges for broader clinical translation.
• Ultrasound Parameters: The optimal ultrasound dosage, frequency, and safety profile for human applications remain to be standardized.
• Long-term Biocompatibility: Although acute toxicity was minimal in animal models, longer-term studies are necessary to fully assess potential side effects of both the nanoplatform and the imaging dye.
• Specificity of Targeting: Tumor heterogeneity and variable folate receptor expression may affect the universality of the targeting strategy.

Despite these challenges, the modular nature of the FNUC design—especially the use of a near infrared fluorescent probe for in vivo imaging—facilitates adaptation to other tumor types or molecular targets, pending further validation.

Protocol Parameters

• Cu Single-Atom MOF Synthesis: Coordinate Cu²⁺ with NH₂-UiO-66 under nitrogen atmosphere; confirm single-atom dispersion via EXAFS and XANES.
• Folic Acid Modification: Conjugate folic acid via EDC/NHS coupling to enable tumor targeting.
• NIR-II Dye Labeling: Couple IR-1061 to the nanoplatform post-synthesis; prepare IR-1061 in DMSO at ≥25.65 mg/mL as per product guidance; avoid long-term solution storage.
• Ultrasound Activation: Apply US at 1 MHz, 1.5 W/cm², for 5–10 minutes to enhance ROS generation in vitro or in vivo.
• Fluorescence Imaging: Excite at appropriate NIR-II wavelength (typically ~1060 nm); image at 24–48 hours post-injection to monitor biodistribution.

Research Support Resources

For researchers aiming to replicate or extend these workflows, IR-1061 (SKU C8242) is a near infrared fluorescent dye specifically designed for in vivo OTN-NIR imaging, with high solubility in DMSO and robust emission in the NIR-II window. Its properties are well-suited for deep tissue imaging applications, as demonstrated in the reference study and related internal protocols. APExBIO provides detailed handling, purity, and storage specifications to support rigorous experimental reproducibility. IR-1061 is intended for research use only and should be handled accordingly.